Symbiosis bolsters in-house analytical testing with £1M investment
The investment will give Symbiosis greater control over sample testing timelines
Symbiosis Pharmaceutical Services, a UK-headquartered contract manufacturing organisation (CMO) that provides GMP aseptic fill and finish services, is expanding its in-house analytical testing capabilities with a £1 million investment.
This investment will see the introduction of in-house testing capabilities for both analytical chemistry and microbiology, and will include dedicated microbiology laboratories as well as temperature and humidity-controlled stability storage capabilities. These will be located adjacent to the company’s existing GMP manufacturing suites in Stirling, Scotland.
Construction of the laboratories began in June of this year and the first microbiology testing capabilities will be qualified and available to support an international client base from the first quarter of 2023. Further microbiology and chemistry capabilities will be qualified and introduced throughout 2023.
Symbiosis also announced the appointment of Alison Clayton as Head of Analytical Services to lead the expansion of analytical testing capabilities. She said the company would take a phased approach to building in-house chemistry and microbiology laboratory capabilities and will eventually offer ‘an enhanced suite of testing capabilities, including sterility, bioburden and endotoxin testing as well as analytical chemistry.’
The company is expected to hire up to 20 additional skilled life sciences staff by the end of next year to support this new testing capability.
CEO of Symbiosis, Colin MacKay commented: ‘This investment is another clear statement of our continuing ambition to strengthen our service offering in response to the demands from existing clients and to position Symbiosis to attract further global biotechnology and pharmaceutical clients in the future.’
The new laboratories will be located in the Logie Court building, one of the three buildings on the Stirling Innovation Park in the UK from which Symbiosis operates.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company
After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. -
News PharmaKure gains authorisation for next stage testing on Alzheimer's treatment
Clinical stage pharmaceutical company PharmaKure gains permission from UK authorities to enter into further testing for PK051 for the treatment of patients with mild cognitive impairment associated with Alzheimer's disease. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News Navigating the Future: Challenges and Opportunities in Pharma Innovation and Investment – CPHI Barcelona 2023 Roundtable Report
In this comprehensive downloadable report, hear from a range of experts in finance and investment in the pharma industry on what investment trends will be shaping the future of the industry, in Catalonia, and the wider world. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance